SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of Directors ...
The Company finishes 2025 with strong Q4 performance, expects 20-22% revenue growth in 2026, and promotes Ross Muken to CEO BOSTON and ROLLE, Switzerland, Jan. 12, 2026 /PRNewswire/ -- SOPHiA GENETICS ...
BETHESDA, MD – November 13, 2025 | The American College of Medical Genetics and Genomics (ACMG) announced today that Melanie Wells, MPH, CAE, Chief Executive Officer of ACMG and the ACMG Foundation ...
The Company finishes 2025 with strong Q4 performance, expects 20-22% revenue growth in 2026, and promotes Ross Muken to CEO Revenue of approximately $77 million, representing an increase of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results